The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moriuchi, M.
Right arrow Articles by Moriuchi, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moriuchi, M.
Right arrow Articles by Moriuchi, H.
Right arrowPubmed/NCBI databases
*OMIM
*Substance via MeSH
Medline Plus Health Information
*Dietary Proteins
The Journal of Immunology, 2001, 166: 4231-4236.
Copyright © 2001 by The American Association of Immunologists

A Milk Protein Lactoferrin Enhances Human T Cell Leukemia Virus Type I and Suppresses HIV-1 Infection1

Masako Moriuchi2,* and Hiroyuki Moriuchi2,3,*,{dagger}

* Division of Medical Virology, Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Medical Sciences; and {dagger} Department of Pediatrics, Nagasaki University School of Medicine, Nagasaki, Japan


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Human T cell leukemia virus type I (HTLV-I) and HIV-1, causative agents of adult T cell leukemia/lymphoma and AIDS, respectively, are transmitted vertically via breast milk. Here we demonstrate that lactoferrin, a milk protein that has a variety of antimicrobial and immunomodulatory activities, facilitates replication of HTLV-I in lymphocytes derived from asymptomatic HTLV-I carriers and transmission to cord blood lymphocytes in vitro. Transient expression assays revealed that lactoferrin can transactivate HTLV-I long terminal repeat promoter. In contrast, lactoferrin inhibits HIV-1 replication, at least in part, at the level of viral fusion/entry. These results suggest that lactoferrin may have different effects on vertical transmission of the two milk-borne retroviruses.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Human T cell leukemia virus type I (HTLV-I)4 is a causative agent of a fatal hemological malignancy known as adult T cell leukemia/lymphoma and a complex neurological disorder designated as HTLV-I-associated myelopathy/tropical spastic paraparesis (1, 2, 3). HTLV-I infection has been found to cluster in certain geographic areas including southwestern Japan, the Caribbean, and central Africa (1, 2, 3). Within such endemic areas, HTLV-I has been transmitted vertically from mother to nursing infant via breast milk, and horizontally by sexual contacts. Milk-borne infection of HTLV-I was supported by the presence of infected cells in milk from carrier mothers (4) and by the experimental transmission of the virus to animals by oral administration of the carrier’s breast milk (5, 6, 7). An intervention in Nagasaki, an endemic area in southwestern Japan by refrain from breast-feeding blocked >80% of mother-to-infant transmission of HTLV-I (8). These studies clearly indicate that breast milk has been an important vehicle of HTLV-I for the maintenance in human populations, and also implicate that components in breast milk may help establish transmission of the virus.

In contrast to HTLV-I, it is generally considered that HIV-1, another human retrovirus, has been recently introduced to Homo sapiens. Milk-borne infection contributes considerably to vertical transmission of this deadly virus (9); however, whether breast milk components influence HIV-1 infection remains largely unknown.

To address these issues, we started to investigate whether breast milk components can influence replication of the two retroviruses. In this study we demonstrate that a milk protein lactoferrin (Lf) can facilitate replication of HTLV-I by up-regulating viral expression, whereas it can inhibit replication of HIV-1 by interfering with viral fusion/entry.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Reagents

Recombinant human (h) Lf, provided by Agennix (Houston, TX), was derived from Aspergillus awamori and had a purity of 99.4%. Where indicated, hLf was heat-denatured by incubating at 56°C for 1 h. Bovine (b) Lf, provided by Morinaga Milk Industry (Kanagawa, Japan), was derived from bovine milk. In experiments aimed to compare effects of iron-saturated hLf and apolactoferrin, we used human milk-derived hLf reagents that had been purchased from Sigma (St. Louis, MO). PMA, ionomycin, AZT, and mitomycin C (MMC) were also purchased from Sigma.

Cells, virus, and infection

PBMCs were isolated from HTLV-I-seropositive or -seronegative healthy individuals (Nagasaki Red Cross Blood Center, Nagasaki, Japan), as described previously (10). Cord blood mononuclear cells (CBMCs) were provided by the Pre-and Post-Natal Care Unit, Nagasaki University School of Medicine Hospital with consent by donors.

For HTLV-I infection studies, unfractionated PBMCs obtained from HTLV-I carriers were propagated with RPMI 1640 supplemented with 10% heat-inactivated FBS in the presence or absence of Lf and/or AZT. Also, PBMCs obtained from HTLV-I-seronegative healthy donors were infected with purified HTLV-I virions (Advanced Biotechnologies, Columbia, MD) in the presence or absence of Lf. For HTLV-I transmission studies, CBMCs were cocultured with MMC-treated PBMCs obtained from HTLV-I carriers in the presence or absence of Lf. Replication of HTLV-I was monitored by HTLV-I p19 Ag detection ELISA as per manufacturer’s instruction (Cellular Products, Buffalo, NY).

For HIV-1 infection studies, PBMCs obtained from healthy donors seronegative for both HIV-1 and HTLV-I were infected with HIV-1 AD8 at an approximate multiplicity of infection of 0.05, or PBMCs obtained from an asymptomatic HIV-1 carrier were incubated in the presence or absence of Lf. Replication of HIV-1 was monitored by reverse transcriptase (RT) assays as described previously (10, 11).

Plasmids and transient expression assays

Plasmid pU3R-luc, which contains HTLV-I long terminal repeat (LTR) U3R region followed by the luciferase gene, was a gift of K.-T. Jeang (National Institute of Allergy and Infectious Diseases, Bethesda, MD). Plasmids pHIV-1 LTR-luc and pCMV-luc contain HIV-1 LTR or human CMV major immediate-early promoter (MIEP), respectively, followed by the luciferase gene. Transfections of PBMCs or CBMCs and luciferase assays were performed as described previously (12).

Recombinant vaccinia vectors and fusion assays

Recombinant vaccinia viruses (rVVs) were propagated as described previously (13, 14). rVV expressing HTLV-I Env (vWR-Env17) was a gift of H. Shida (Hokkaido University, Hokkaido, Japan) (15). For fusion assays, BSC-1 cells were infected with vCB21R (a rVV encoding the lacZ gene under the control of T7 promoter) as well as a rVV expressing the indicated viral Env at a multiplicity of infection of 10. Primary CD4+ T cells obtained from healthy volunteers were infected with vTF7-3 (a rVV expressing T7 RNA polymerase) at a multiplicity of infection of 10 each. After a 10-h culture at 37°C, both fusion effectors (BSC-1 cells) and fusion targets (CD4+ T cells) were mixed and incubated at 37°C for 6 h in the presence of cytosine arabinoside, and the mixed cell culture lysates were subjected to {beta}-galactosidase assays. Where indicated, hLf (100 µg/ml) was added to CD4+ T cell cultures 1 h before and throughout cocultivation.

Single-round virus replication assays

Single-round virus replication assays were performed using replication-incompetent luciferase reporter viruses that had been pseudotyped by Env derived from either T-tropic (X4) HIV-1 HXB2, M-tropic (R5) HIV-1 JR-FL, or amphotropic murine leukemia virus (AMLV), as described previously (13). In brief, 5 x 105 cells were mock-treated or treated with hLf (100 µg/ml) for 1 h at 37°C and then infected with the indicated virus stock (50,000 cpm RT activity). Three hours later, the infected cells were resuspended in RPMI 1640/10% FBS with or without hLf (100 µg/ml), and incubated for 3 days. Luciferase assays were performed using commercially available reagents (Promega, Madison, WI).

Flow cytometric analysis

Cell surface expression of CD69, CD25, CCR5, or CXC chemokine receptor 4 (CXCR4) was determined by staining cells with monoclonal anti-CD69 Ab FITC-conjugate, anti-CD25 Ab FITC-conjugate, anti-CCR5 Ab 2D7 PE-conjugate, or anti-CXCR4 Ab 12G5 PE-conjugate (PharMingen, San Diego, CA), respectively, and by analyzing in FACScan (Becton Dickinson Immunocytometry Systems, Mountain View, CA), as described previously (13).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Lf induces replication of HTLV-I

Effect of Lf on HTLV-I infection was first evaluated in PBMCs derived from asymptomatic carriers. In preliminary experiments for selected donors, induction of HTLV-I replication that was determined by p19 Ag levels in cell-free culture supernatants was detected as soon as 3 days after stimulation with Lf, and peak p19 Ag titers were obtained by day 7 in most cases (data not shown). Therefore, p19 Ag titers were determined on day 7 in the subsequent experiments. HTLV-I replication was enhanced up to 5- to 10-fold by stimulation with hLf or bLf in a dose-dependent manner (Table IGo). Similarly enhanced HTLV-I replication was obtained in hLf-stimulated PBMCs that were infected with cell-free HTLV-I virions (Table IGo). Heat denaturation of hLf abrogated its effects on HTLV-I replication (Table IIGo). Apolactoferrin also induced HTLV-I replication, although it appeared to have less pronounced effects (3- to 5-fold induction) as compared with iron-saturated Lf (5- to 10-fold induction) (data not shown). Because several different sources of Lf (recombinant, human milk, or bovine milk) had similar effects on HTLV-I infection as above, the ability of Lf to induce viral replication appears to be specific. Treatment with AZT (2 µM) resulted in a markedly decreased expression of p19 Ag (Table IIIGo). Because AZT has no antiretroviral effect on PBMCs already infected with HTLV-I (16), profound suppression of p19 expression by AZT would indicate that induction of HTLV-I expression in the presence of Lf required expansion of HTLV-I infection. Addition of Lf to the cell culture medium did not appear to influence cell viability or expression of CD69 or CD25, as determined by trypan blue exclusion and flow cytometric analysis, respectively (data not shown), suggesting that Lf effect does not rely on cell activation/proliferation. Thus, these results suggest that Lf may induce HTLV-I replication in carriers’ PBMCs.


View this table:
[in this window]
[in a new window]
  		Table I. Induction by Lf of HTLV-I expression in PBMC derived from asymptomatic HTLV-I carriers1

 

View this table:
[in this window]
[in a new window]
  		Table II. Heat denaturation of Lf abrogates its effects on HTLV-I replication1

 

View this table:
[in this window]
[in a new window]
  		Table III. Inhibition by AZT of Lf-induced HTLV-I replication in carriers’ PBMC1

 
We next investigated whether Lf can accelerate transmission of HTLV-I to CBMCs. Uninfected CBMCs were cocultured with MMC-treated carriers’ PBMCs at a ratio of 10:1 in the presence or absence of Lf. It has been shown that MMC-treated cells can no longer support new cycles of retroviral infection (17). As shown in Table IVGo, p19 level in the coculture supernatants was increased by treatment with Lf. Cultures of MMC-treated carrier PBMC alone produced a much reduced amount of p19 Ag even in the presence of Lf, suggesting that expansion to susceptible CBMCs is required for the induction of HTLV-I replication. Similar results were obtained for experiments of HTLV-I transmission to adult PBMCs (data not shown). These results imply that Lf can expand viral infection to other cells including neonatal or adult lymphocytes.


View this table:
[in this window]
[in a new window]
  		Table IV. Expansion by Lf of HTLV-I infection to CBMCs1

 
Lf inhibits replication of HIV-1

Lf has been shown to display antiviral activity against a diverse array of viruses including HIV-1, another human retrovirus (18, 19, 20, 21). As demonstrated by those studies, Lf treatment inhibited HIV-1 replication in a dose-dependent manner (Table VGo). Thus, it appears that a milk protein Lf has opposite effects on the two human retroviruses that are transmitted via breast milk.


View this table:
[in this window]
[in a new window]
  		Table V. Inhibition of HIV-1 replication by Lf1

 
Lf transactivates HTLV-I LTR promoter

A variety of immunomodulatory activities have been attributed to Lf (22), indicating that sequestration of iron is not the only function of this protein. Recently, Lf has been shown to regulate transcription (23); therefore, Lf may exert its function, at least in part, through transcriptional regulation.

To explore the possibility that Lf can transactivate HTLV-I LTR promoter, transient expression assays were performed. PBMCs or CBMCs obtained from HTLV-I-uninfected individuals were transfected with pU3R-luc, and cell lysates were prepared for luciferase assays 2 days after transfection. Where indicated, transfected cells were stimulated with hLf for 12 h before harvest. As shown in Fig. 1Go, hLf could transactivate HTLV-I LTR but had little effect on activity of HIV-1 LTR or human cytomegalovirus (HCMV) MIEP, whereas stimulation with PMA/ionomycin transactivated all these promoters (Fig. 1Go; data not shown). Thus, our results strongly suggest that Lf can induce HTLV-I replication by up-regulating HTLV-I LTR promoter activity.



View larger version (36K):
[in this window]
[in a new window]
  		FIGURE 1. Stimulation of PBMCs or CBMCs with Lf up-regulates HTLV-I LTR activity. Forty million PBMCs or CBMCs were transfected with 10 µg of pU3R-luc (A and D), 20 µg of pHIV-1 LTR-luc (B and E), or 5 µg of pCMV-luc (C), and divided into four wells. Two days after transfection, the cells were either untreated or treated with the indicated amounts of recombinant hLf (Agennix) (A-C) or PMA/ionomycin (D and E) for 12 h before harvest. Luciferase activity in the cell lysates was determined as described previously (12 ). Results are means ± SEM from five different experiments.

 
Lf inhibits retrovirus infections at the level of fusion/entry

To explore the mechanism whereby HIV-1 infection is inhibited by Lf, we next investigated effects of Lf on viral fusion/entry, another critical step during viral replicative cycle. First, Env glycoproteins derived from HIV-1 or HTLV-I were expressed on the cell surfaces using rVV, and fusogenicity of these cells with CD4+ T cells was determined. As shown in Fig. 2Go, Lf markedly down-regulated fusogenicity with HIV-1 Env, irrespective of their coreceptor usage. Flow cytometric analyses also demonstrated that expression of CCR5 or CXCR4 was not significantly modified by stimulation with Lf (data not shown). Lf also down-regulated fusogenicity with HTLV-I Env, although to a lesser degree.



View larger version (20K):
[in this window]
[in a new window]
  		FIGURE 2. Lf inhibits cell-cell fusion mediated by viral Env glycoproteins. Primary CD4+ T cells (fusion targets) were infected with vTF7-3 (expressing the T7 RNA polymerase). BSC-1 cells (fusion effectors) were infected with vCB21R (encoding the lacZ gene under the control of the T7 promoter) as well as vWT or the indicated rVV encoding viral Env shown in parentheses. The two sets of cells were mixed in the presence or absence of recombinant hLf (100 µg/ml; Agennix), and {beta}-galactosidase activity in the infected cell lysates was determined 4 h after mixing. Fusion index indicates {beta}-galactosidase activity relative to those in vWT-infected cultures in the absence of hLf. Results are means ± SEM from three (for HIV-1 Env experiments) or six (for HTLV-I Env experiments) independent experiments.

 
HIV-1 Env-mediated fusion/entry was further investigated by another system. CD4+ T cells were infected with a replication-incompetent, luciferase-reporter molecular clone NL4–3luc-R-E- that had been pseudotyped by Env from X4-HIV-1, R5-HIV-1, or AMLV, and viral expression was assessed by luciferase activity. As shown in Fig. 3Go, pretreatment, but not post-treatment, of the cells with hLf markedly down-regulated HIV-1 expression. This effect was not dependent on coreceptor usage and was also observed in AMLV Env-pseudotyped virus. Taken together with previous studies suggesting that Lf is capable of inhibiting a number of viral infections at early stage(s) of replicative cycle (18, 19, 21), our results imply that Lf may interfere with cellular entry of a number of enveloped viruses in a nonspecific fashion.



View larger version (35K):
[in this window]
[in a new window]
  		FIGURE 3. Single-round viral replication assays. Primary CD4+ T cells were infected with NL4-3luc-R-E- pseudotyped by the indicated viral Env. Where indicated, cells were treated with recombinant hLf (100 µg/ml; Agennix) for 1 h before infection (pre) or immediately after infection (post). Luciferase activity in the infected cell lysates was determined 3 days postinfection. Results are shown as luciferase activity relative to those in mock-treated cells from three independent experiments.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Milk-borne transmission of HTLV-I accounts for a majority of cases of vertical transmission, and infection during the infantile period is usually a prerequisite for the development of leukemia during late adulthood (1, 2, 3). Because HTLV-I appears to have coexisted with Homo sapiens for quite a long time by efficacious transmission via breast milk and semen, we hypothesized that HTLV-I may take advantage of constituent(s) in these body fluids. Lf is a mammalian iron-binding glycoprotein present in a variety of body fluids including breast milk, tears, semen, and plasma, and has been attributed to antimicrobial effects and immunomodulatory activities (22). In this study we have demonstrated that Lf is capable of enhancing HTLV-I infection.

Induction of HTLV-I replication by Lf is mediated, at least in part, by transcriptional activation of HTLV-I LTR promoter. Lf induction of HTLV-I LTR activity is specific, because Lf had little effect on the HIV-1 LTR or HCMV MIEP activity. Recently, it has been shown that Lf is transferred to the nucleus, directly binds to DNA, and is capable of activating transcription (23); however, no Lf-inducible promoter has actually been identified yet. Therefore, this may be the first study to identify a promoter that is transactivated by Lf. The precise mechanism whereby Lf transactivates HTLV-I LTR remains undetermined; it may directly transactivate HTLV-I LTR promoter, or may induce expression of host factor(s) that in turn transactivate the promoter. Interestingly, Lf induction of HTLV-I LTR promoter activity is more prominent in CBMCs than in PBMCs (Fig. 1Go). Although sample numbers are still small, these results may indicate that immature newborn cells may contain larger amounts of host factor(s) that are required for Lf-mediated effect than do adult cells. Such possibilities are currently under investigation.

Lf has been shown to have antiviral activity. Recently, Harmsen et al. showed that Lf inhibits HIV-1 and HCMV infections (18), probably at the level of viral entry (absorption or penetration). By performing two assays (rVV-based fusion assays and single-round viral replication assays), we have confirmed that Lf could inhibit HIV-1 entry into cell. We have also shown that Lf had similar effects on HTLV-I Env-mediated cell-cell fusion, although to a lesser degree. Thus, Lf appears to have the opposite effects on HTLV-I infection, induction of viral expression, and suppression of viral entry. Therefore, we hypothesize that the ability of Lf to enhance viral infection at later step(s) may overcome its negative effect on earlier step(s) in case of HTLV-I; however, infection with other viruses (e.g., HIV-1, CMV) may be simply suppressed by its inhibitory effect on viral entry. Further investigation is needed to clarify this issue.

Lf is a major milk protein, and the amounts of Lf are 5~7 mg/ml in colostrum, 1~3 mg/ml in mature milk, 1.5~2.2 mg/ml in tears, and 0.5~1 mg/ml in seminal fluid (24, 25). Therefore, we believe that the concentration used in this study (up to 100 µg/ml) is physiologically relevant even after dilution in the gastrointestinal and genital tracts. Although the precise portal of entry for HTLV-I or HIV-1 across mucosal surfaces in infants is unknown (9), it is not unreasonable to hypothesize that Lf actually exerts its effects on viral transmission or infection in vivo. Finally, it is important to rule out the possibility that other components or contaminants rather than Lf contain the relevant activity. However, based upon our observations that several different sources (recombinant, human milk, or bovine milk) of Lf had similar effects, it is reasonable to assume that Lf did actually exhibit activities demonstrated in this study.

In summary, this study suggested that a milk protein Lf enhances replication and transmission of HTLV-I and suppresses infection with HIV-1, the two milk-borne pathogens, and may have implications for host-pathogen interactions during transmission via milk or other biological secretions.


   Acknowledgments
 
We thank K.-T. Jeang for providing pU3R-luc; Agennix and Morinaga Milk Industry for Lf products; Nagasaki Red Cross Blood Center and Pre-and Post-Natal Care Unit (Nagasaki University Hospital) for blood samples; H. Shida for vWR-Env17; E. Berger for other rVV constructs; N. Landau and J. Sodroski for plasmids used in single-round virus replication assays; T. Theodore for HIV-1 AD8; S. Katamine and H. Ishimaru for critical review; and K. Iijima and M. Yokoyama for technical assistance and graphic work.


   Footnotes
 
1 This work was supported in part by grants from The Japan Leukemia Research Foundation, The Mother and Child Health Foundation, and The Morinaga Hohshi-kai. Back

2 M.M. and H.M. contributed equally to this project. Back

3 Address correspondence and reprint requests to Dr. Hiroyuki Moriuchi, Department of Pediatrics, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. Back

4 Abbreviations used in this paper: HTLV-I, human T-cell leukemia virus type I; Lf, lactoferrin; hLf, human lactoferrin; bLf, bovine lactoferrin; MMC, mitomycin C; CBMCs, cord blood mononuclear cells; RT, reverse transcriptase; LTR, long terminal repeat; MIEP, major immediate early promoter; rVV, recombinant vaccinia virus; AMLV, amphotropic murine leukemia virus; CXCR4, CXC chemokine receptor 4; HCMV, human cytomegalovirus. Back

Received for publication October 19, 2000. Accepted for publication January 8, 2001.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Hollsberg, P., D. A. Hafler. 1993. Pathogenesis of diseases induced by human lymphotropic virus type I infection. N. Engl. J. Med. 328:1173.[Free Full Text]
  2. Uchiyama, T.. 1997. Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu. Rev. Immunol. 15:15.[Medline]
  3. Yamaguchi, K.. 1994. Human T-lymphotropic virus type I in Japan. Lancet 343:213.[Medline]
  4. Kinoshita, K., S. Hino, T. Amagasaki, S. Ikeda, Y. Yamada, J. Suzuyama, S. Momita, K. Toriya, S. Kamihira, M. Ichimaru. 1984. Demonstration of adult T-cell leukemia virus antigen in milk from three sero-positive mothers. Jpn. J. Cancer Res. (GANN) 75:103.
  5. Kinoshita, K., K. Yamanouch, S. Ikeda, S. Momita, T. Amagasaki, H. Soda, M. Ichimaru, R. Moriuchi, S. Katamine, T. Miyamoto, S. Hino. 1985. Oral infection of a common marmoset with human T-cell leukemia virus type-I (HTLV-I) by inoculating fresh human milk of HTLV-I carrier mothers. Jpn. J. Cancer Res. (GANN) 76:1147.[Medline]
  6. Iwahara, Y., N. Takehara, R. Kataoka, T. Sawada, Y. Ohtsuki, H. Nakachi, T. Maehama, T. Okayama, I. Miyoshi. 1990. Transmission of HTLV-I to rabbits via semen and breast milk from seropositive healthy persons. Int. J. Cancer 45:980.[Medline]
  7. Hirose, S., S. Kotani, Y. Uemura, M. Fujishita, H. Taguchi, Y. Ohtsuki, I. Miyoshi. 1988. Milk-borne transmission of human T-cell leukemia virus type I in rabbits. Virology 162:487.[Medline]
  8. Hino, S., S. Katamine, H. Miyata, Y. Tsuji, T. Yamabe, T. Miyamoto. 1996. Primary prevention of HTLV-I in Japan. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 13:(Suppl. 1):S199.
  9. Van de Perre, P.. 1999. Transmission of human immunodeficiency virus type 1 through breast-feeding: how can it be prevented?. J. Infect. Dis. 179:(Suppl. 3):S405.
  10. Moriuchi, H., M. Moriuchi, C. Combadiere, P. M. Murphy, A. S. Fauci. 1996. CD8+ T-cell-derived factor(s), but not {beta}-chemokines RANTES, MIP-1{alpha}, and MIP-1{beta}, suppress HIV-1 replication in monocytes/macrophages. Proc. Natl. Acad. Sci. USA 93:15431.
  11. Moriuchi, H., M. Moriuchi, A. S. Fauci. 1998. Factors secreted by HTLV-I-infected cells can enhance or inhibit replication of HIV-1 in HTLV-I-uninfected cells: implications for in vivo coinfection with HTLV-I and HIV-1. J. Exp. Med. 187:1689.[Abstract/Free Full Text]
  12. Moriuchi, H., M. Moriuchi, A. S. Fauci. 1997. NF-{kappa}B potently upregulates the promoter activity for RANTES, a chemokine that inhibits HIV-1 infection. J. Immunol. 158:3483.[Abstract]
  13. Moriuchi, H., M. Moriuchi, J. Arthos, J. Hoxie, A. S. Fauci. 1997. Promonocytic U937 clones expressing CD4 and CXCR4 are resistant to infection with and cell-to-cell fusion with T-tropic HIV-1. J. Virol. 71:9664.[Abstract]
  14. Feng, Y., C. C. Broder, P. E. Kennedy, E. A. Berger. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G-protein-coupled receptor. Science 272:872.[Abstract]
  15. Shida, H., T. Tochikura, T. Sato, T. Konno, K. Hirayoshi, M. Seki, Y. Ito, M. Hatanaka, Y. Hinuma, M. Sugimoto, et al 1987. Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection. EMBO J. 6:3379.[Medline]
  16. Macchi, B., I. Faraoni, J. Zhang, S. J., C. Grelli, A. Favalli, A. Mastino, E. Bonmasssar. 1997. AZT inhibits the transmission of human T cell leukemia/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro. J. Gen. Virol. 78:1007.[Abstract]
  17. Busch, M. P., T. H. Lee, J. Heitman. 1992. Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type 1 infection: implications for transfusion support of infected individuals. Blood 80:2128.[Abstract/Free Full Text]
  18. Harmsen, M. C., P. J. Swart, M. P. de Bethune, R. Pauwels, E. De Clercq, T. H. The, D. F. K. Meijer. 1995. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J. Infect. Dis. 172:380.[Medline]
  19. Puddu, P., P. Borghi, S. Gessani, P. Valenti, F. Belardelli, L. Seganti. 1998. Antiviral effect of bovine lactoferrin saturated with metal ions on early steps of human immunodeficiency virus type 1 infection. Int. J. Biochem. Cell Biol. 30:1055.[Medline]
  20. Swart, P. J., M. E. Kuipers, C. S. Pauwels, M. P. de Bethune, E. de Clercq, D. K. F. Meijer, J. G. Huisman. 1996. Antiviral effects of milk proteins: acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro. AIDS Res. Hum. Retroviruses 12:769.[Medline]
  21. Valenti, P., M. Marchetti, F. Superti, M. G. F., P. Amendolia, S. Puddu, P. Gessani, F. Borghi, G. Belardelli, G. Antonini, L. Seganti. 1998. Antiviral activity of lactoferrin. Adv. Exp. Med. Biol. 443:199.[Medline]
  22. Brock, J.. 1995. Lactoferrin: a multifunctional immunoregulatory protein?. Immunol. Today 16:417.[Medline]
  23. He, J., P. Furmanski. 1995. Sequence specificity and transcriptional activation in the binding of lactoferrin to DNA. Nature 373:721.[Medline]
  24. Masson, P. L., J. F. Heremans. 1971. Lactoferrin in milk from different species. Comp. Biochem. Physiol. 39B:119.
  25. Levay, P. F., M. Viljoen. 1995. Lactoferrin: a general review. Haematologica 80:252.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
K. Hieshima, D. Nagakubo, T. Nakayama, A.-K. Shirakawa, Z. Jin, and O. Yoshie
Tax-Inducible Production of CC Chemokine Ligand 22 by Human T Cell Leukemia Virus Type 1 (HTLV-1)-Infected T Cells Promotes Preferential Transmission of HTLV-1 to CCR4-Expressing CD4+ T Cells
J. Immunol., January 15, 2008; 180(2): 931 - 939.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
R. M. Novak, B. A. Donoval, P. J. Graham, L. A. Boksa, G. Spear, R. C. Hershow, H. Y. Chen, and A. Landay
Cervicovaginal Levels of Lactoferrin, Secretory Leukocyte Protease Inhibitor, and RANTES and the Effects of Coexisting Vaginoses in Human Immunodeficiency Virus (HIV)-Seronegative Women with a High Risk of Heterosexual Acquisition of HIV Infection
Clin. Vaccine Immunol., September 1, 2007; 14(9): 1102 - 1107.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
C. Johansson, M. Jonsson, M. Marttila, D. Persson, X.-L. Fan, J. Skog, L. Frangsmyr, G. Wadell, and N. Arnberg
Adenoviruses Use Lactoferrin as a Bridge for CAR-Independent Binding to and Infection of Epithelial Cells
J. Virol., January 15, 2007; 81(2): 954 - 963.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
S. H. Kazmi, J. R. Naglik, S. P. Sweet, R. W. Evans, S. O'Shea, J. E. Banatvala, and S. J. Challacombe
Comparison of Human Immunodeficiency Virus Type 1-Specific Inhibitory Activities in Saliva and Other Human Mucosal Fluids
Clin. Vaccine Immunol., October 1, 2006; 13(10): 1111 - 1118.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. Moriuchi and H. Moriuchi
Induction of Lactoferrin Gene Expression in Myeloid or Mammary Gland Cells by Human T-Cell Leukemia Virus Type 1 (HTLV-1) Tax: Implications for Milk-Borne Transmission of HTLV-1
J. Virol., July 15, 2006; 80(14): 7118 - 7126.
[Abstract] [Full Text] [PDF]

Home page
 J Hum LactHome page
S. U. Hartmann, C. M. Berlin, and M. K. Howett
Alternative Modified Infant-Feeding Practices to Prevent Postnatal Transmission of Human Immunodeficiency Virus Type 1 Through Breast Milk: Past, Present, and Future
J Hum Lact, February 1, 2006; 22(1): 75 - 88.
[Abstract] [PDF]

Home page
 J. Virol.Home page
M. Moriuchi and H. Moriuchi
Cell-Type-Dependent Effect of Transforming Growth Factor {beta}, a Major Cytokine in Breast Milk, on Human Immunodeficiency Virus Type 1 Infection of Mammary Epithelial MCF-7 Cells or Macrophages
J. Virol., December 1, 2004; 78(23): 13046 - 13052.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. Moriuchi and H. Moriuchi
Seminal Fluid Enhances Replication of Human T-Cell Leukemia Virus Type 1: Implications for Sexual Transmission
J. Virol., November 15, 2004; 78(22): 12709 - 12711.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moriuchi, M.
Right arrow Articles by Moriuchi, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moriuchi, M.
Right arrow Articles by Moriuchi, H.
Right arrowPubmed/NCBI databases
*OMIM
*Substance via MeSH
Medline Plus Health Information
*Dietary Proteins

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS